FDA Seeks Comments on Drug Shortages

As reported last month (“Rheumatologists Struggle with Drug Shortages,” October 2011, p. 51), a bill (S. 296) proposed in the U.S. Senate would require drug manufacturers to notify the U.S. Food and Drug Administration (FDA) of factors that might lead to a drug shortage.

The FDA invites public comments regarding the Center for Drug Evaluation and Research’s approach to addressing drug shortages, and seeks insight about the causes and impacts of drug shortages and possible strategies for preventing or mitigating drug shortages. Because this issue affects the rheumatology community, the ACR encourages members to comment by December 23, 2011.

Comments may be submitted online at www.reg ulations.gov. To read the Federal Register announcement and for instructions to submit comments in writing, visit www.gpo.gov/fdsys/pkg/FR-2011-09-29/pdf/2011-25116.pdf.

While not yet at a ‘catastrophic’ level, shortages are becoming more common

Information on New Approvals and Medication Safety

Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

(Reuters Health)—U.S. emergency rooms are increasingly running short on medications, including many that are needed for life-threatening conditions, a recent study documents. Since 2008, the number of shortages has risen by more than 400%, researchers found. Half of all emergency room shortages were for life-saving drugs, and for one in 10 there were no available…

FDA Seeks Comments on Drug Shortages

Rheumatologists Struggle with Drug Shortages

Drug Updates

Psoriatic Arthritis Drugs at a Glance, 2023

Drug Shortages in U.S. Emergency Departments on the Rise

Related Articles